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Plaisante justice, qu’une rivière borne!
Vérité au-deçà des Pyrénées, erreur
au-delà.
Funny justice that is marked by a river!
What is truth on this side of the Pyre-
nees is a mistake on the other side.
(Translation by DMD)
From the book “Pensées” by Blaise
Pascal (1623–1662)
French mathematician, physicist,
inventor, writer, and philosopher.
This article is an unabashed drumroll for
increased recognition and treatment of
catatonia in autism spectrum disorders
(ASD). This new diagnostic and treat-
ment paradigm has emerged during the last
decade (1, 2) and is supported by changes
in catatonia classification in DSM-5 (3)
purporting to boost recognition of pedi-
atric catatonia and catatonia in ASD (4).
Findings are summarized, a vignette is pre-
sented, and a Decalogue (or“10 command-
ments”) is offered covering rules for assess-
ment, diagnosis, treatment, and research
in the field of catatonia in ASD. Unlike
the biblical Decalogue handed to Moses on
Mount Sinai, these rules are hardly divine,
do not mark universal truths, are mainly
based on clinical experience, and need to be
calibrated further as knowledge increases.
They do represent the best available rec-
ommendations, at least in my opinion, for
future research and in order to achieve pos-
itive outcomes that are equally rewarding
for the patients and their families, and for
their physicians.
PREVALENCE, ASSESSMENT, AND
TREATMENT OF CATATONIA IN ASD
Catatonia is a severe but treatable syn-
drome that warrants prompt diagnosis
and treatment with benzodiazepines and
electroconvulsive therapy (ECT) and that
occurs in patients of all ages, including chil-
dren and adolescents (5–7). The syndrome
becomes critical and life threatening in its
malignant form when aggravated by fever
and autonomic dysfunction. Advances in
catatonia research have segued into the field
of autism over the last 10 years. Catatonia
in ASD has been increasingly recognized at
a rate of 4–17% in adolescents and adults
with ASD (Table 1). No systematic studies
have been done in preadolescent and older
(>60 years old) patients. The vignette of
a 10-year-old boy with catatonia and ASD
that is presented below shows its occur-
rence in preadolescence. There are no cases
in the literature, to my knowledge, describ-
ing catatonia in patients with ASD older
than 60.
Symptoms that should alert the clin-
ician for catatonia in adolescents and
young adults with ASD are markedly
increased psychomotor slowness, which
may alternate with excessive motor activ-
ity, apparently purposeless, and not influ-
enced by external stimuli, extreme nega-
tivism or muteness, stereotypy, peculiari-
ties of voluntary movement, echolalia, or
echopraxia. The diagnosis of catatonia in
ASD is made applying known clinical signs
of catatonia and using standardized cata-
tonia rating scales to assess the scope and
the severity of the symptoms. In addition,
the diagnosis may be supported by a ben-
zodiazepine (most commonly lorazepam)
challenge test, which is known to result in
a marked, albeit temporary, improvement.
Stressful life events, the loss of rou-
tine, experiences of loss, interpersonal con-
flicts, and discrepancies between the ability
in the patient and parental expectations,
especially in higher functioning autistic
youth, may precipitate catatonia, which
may present in conjunction with other
major psychiatric or medical disorders (13,
14). A medical work-up and comprehen-
sive drug screening is necessary to uncover
medical or toxic conditions.
Benzodiazepines and bilateral ECT,
including maintenance ECT, should be
considered as safe and effective med-
ical treatments for pediatric catatonia and
catatonia in ASD based on case-reports
and case-series (2, 15). Milder cases have
improved with psychological–behavioral
interventions (16). Benzodiazepines, most
commonly lorazepam, are the first-line
treatment, followed by ECT if benzodi-
azepines are not or insufficiently effective.
The duration and intensity of ECT varies
in each case. Although there are reports
of a small number of cases that show
the effective use of right unilateral ECT
in catatonia (17), none of these patients
were diagnosed with ASD. In almost all
cases with ASD, bilateral ECT has been
used (18) and should be considered as the
preferred method until further studies or
experience shows advantages when using
or starting with unilateral ECT. So far con-
cerns of cognitive impairment with bilat-
eral ECT have not emerged. There are now
a few reported cases that have continued
to receive bilateral ECT for several years
to maintain improvement and to prevent
relapse without any indication of cognitive
or neuropsychological worsening (19, 20).
DeJong et al. (18) have recently reviewed
the literature on the efficacy of various
treatments for catatonia in ASD. They
found 22 pertinent articles describing the
treatment of 28 pediatric and adult patients
supporting the use of ECT, high-dose
lorazepam, and behavioral therapy. They
deplore the scarcity of papers and in-depth
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Table 1 | Prevalence studies of catatonia in autism spectrum disorders.
Reference N Design sample population (age, range, and/or mean) %With catatonia (age, range, and/or mean)
Wing and Shah (8) 506 Cross-sectional referred sample with autism (NA) 17 (Age range 15–50 years, mean age=24.6)
Billstedt et al. (9) 120 Longitudinal population sample with autism (age range 17–40 years,
mean age=25.5)
12 (NA)
Ohta et al. (10) 69 Cross-sectional referred sample with autism (NA) 12 (Age range 21–40 years, mean age=28 SD=5.5)
Hutton et al. (11) 135 Longitudinal referred sample with autism (age range 21–57 years,
mean age=35)
4 (NA)
Ghaziuddin et al. (12) 81 Cross-sectional referred sample with autism (mean age=14, SD=2) 16 (NA)
NA, not available.
analyses. They conclude that controlled
multi-centers studies are warranted to
compare treatments and to determine the
optimal treatment for catatonia in ASD.
VIGNETTE
This vignette of a 10-year-old boy diag-
nosed at age 4 with high-functioning ASD,
type “Asperger,” who developed full-blown
catatonia over the course of a few months,
is the synopsis of a case-report that is in
press (21).
At 4 years of age, A was diagnosed
with ASD due to restrictive interests, vocal
and motor tics, specific phobias, atten-
tion deficits, severe aggression, obsessive–
compulsive tendencies, and abnormal
movements in mouth, and repetitive move-
ments. Testing showed an IQ of 80. At
the age of 10, 1 year prior to admission
for catatonia, A became extremely upset
about an incident on school when his best
friend spit on his thermos. Over the next
few days, he became increasingly and exces-
sively fearful that people were deliberately
spitting on him. He stated that the spit
could find its way into his mouth and
then brain where it would ruin his iden-
tity. He refused to leave his room and go to
school and went into violent rages. Over the
next 6 months, several interventions and
medications, including SSRI’s and antipsy-
chotics, were tried to no avail. A medical
work-up included blood work, compre-
hensive drug testing, brain imaging and
lumbar puncture, autoimmune antibod-
ies [lupus serology, pediatric autoimmune
neuropsychiatric disorders associated with
streptococcal infections (PANDAS) serol-
ogy, anti-N -methyl-d-aspartate (NMDA)
receptor antibodies] and was completely
negative.
Six months after onset of symptoms, A
started to have episodes lasting several days
where he would stop speaking, refusing to
eat, and sitting in the same spot in the
hallway. He was diagnosed with catatonia
and was started on lorazepam with positive
effects but the patient took the medication
inconsistently. His condition worsened. A
trial of high-dose-lorazepam given intra-
muscularly was done, with maximum dose
of 24 mg (8 mg IM three times per day),
with only partial response yet no sedation.
Ten months after onset of symptoms, ECT
was started with consent of the parents.
Bilateral ECT was started three times per
week. After three ECT treatments, A started
to speak a few words occasionally, mostly
echoing the words (and body movements)
of others. After six treatments, he started
to allow others to touch him and was spit-
ting less but continued to need help in
all areas of daily function. Over the next
2 weeks ECT was continued and aripipra-
zole was started as an antipsychotic adjunct
and titrated to 20 mg/day.
A continued to make slow progress until
he became fully verbal on day 31 of admis-
sion after the 12th ECT. He carried out
a long conversation with his teacher. He
knew that he was in the hospital, and was
oriented to season but not the month or
day. A stated that he was still concerned
that he would die if someone spit on
him. During the next week, he improved
rapidly and returned to premorbid func-
tioning. He was discharged after two more
ECT treatments. Throughout the course
of ECT, no side effects were noted except
an occasional headache in the afternoon
on the day of ECT. His memory and cog-
nitive function seemed greatly improved
over the course of admission and ECT. At
2-year follow-up, A has had no relapses
of catatonia. Maintenance therapy consists
of lorazepam (4 mg/day) and aripiprazole
(15 mg/day). A has been able to resume
school in special education classes. The par-
ents report that he has been back to baseline
since more than 1 year.
DECALOGUE OF CATATONIA IN AUTISM
SPECTRUM DISORDERS
1. Catatonia is a diagnosable syndrome in
ASD (2).
2. Patients with ASD are prone to develop
catatonia due to concurrent med-
ical and psychological impairments
(13, 22).
3. The treatment of catatonia in ASD is
very specific and consists of benzodi-
azepines and ECT (23).
4. Some severe forms of repetitive self-
injurious behavior (SIB) are best con-
ceptualized as catatonic stereotypy
(with bodily injury) for which ben-
zodiazepines, ECT, and maintenance
ECT are indicated (24, 25).
5. Do not use antipsychotics in the active
phase of catatonia before benzodi-
azepines or ECT is started, in order
to avoid malignant catatonia and neu-
roleptic malignant syndrome (23).
6. A lorazepam (initial administration of
1 or 2 mg po or parentally followed
by increased doses up to 20–30 mg/day
depending on the level of response and
side effects or sedation) or zolpidem (5
or 10 mg po) challenge test verifies the
catatonia diagnosis (23).
7. High dosages of lorazepam, up to 20–
30 mg daily, may be necessary for full
symptom resolution (23) and, sur-
prisingly, are well tolerated without
sedation by some patients.
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8. Bilateral ECT is the definitive treat-
ment for catatonia in ASD when
lorazepam does not bring about swift
or sufficient relief or when fever and
autonomic dysfunction arise. Concur-
rent and synergistic use of lorazepam
and ECT is possible when using
flumazenil to temporarily suspend
the anticonvulsant effects of benzodi-
azepines during ECT (23).
9. Maintenance ECT is a safe treatment
option that is sometimes crucial to
avoid relapse (19, 20).
10. Catatonia provides a window into the
mechanism of autism, and vice versa
(26, 27).
ROSETTA STONE
Catatonia is characterized by repetitive
movements, mutism, posturing, and fran-
tic agitation. These signs are also frequent
in autism yet usually do not amount to
a diagnosis of catatonia unless there is
a sharp and sustained increase of these
symptoms lasting days or weeks. Catato-
nia and autism have widely different his-
torical roots (28). Much can be learned
from the study of catatonia in ASD. The
Rosetta stone was a small stone tablet
containing the same message written in
Greek and two different Egyptian scripts.
The stone was essential for deciphering
Egyptian hieroglyphics. Can the group
of patients who are diagnosed with both
autism and catatonia be like the Rosetta
stone, providing the complete sentences
required for deciphering the mechanisms
of autism and catatonia? Do the syn-
dromes have a common pathophysiology?
Can the successful treatment of catatonia
be applied to all patients that meet cri-
teria for autism and catatonia? Can early
application of treatments for catatonia stop
autistic regression? These questions beg
answers sorely needed by patients and their
families.
Blaise Pascal lamented in the seven-
teenth century over the vagaries of justice.
He observed that blasphemy in one place
(or time) is truth in another place (or time).
The situation is not different in medicine
and also seems to apply to catatonia in
ASD. Detractors interpret catatonia as an
aspecific and undefined epiphenomenon
of another “more valid” disorder such as
a medical disorder, schizophrenia, bipolar
disorder, or obsessive–compulsive disorder,
requiring no specific treatment. For exam-
ple, in the follow-up study of Hutton et al.
(11) of 135 individuals with ASD to at
least the age of 21 years, five individuals
had a relatively sudden onset of catatonia
and obsessive–compulsive disorder. In two
cases, the disorders resolved with treatment
but in the other three there was only a par-
tial recovery. None of these patients was
treated with benzodiazepines or ECT. The
authors ask themselves whether benzodi-
azepines or ECT should have been used in
these cases but then demur: “If the impres-
sion that catatonia develops as a result of
obsessive-compulsive phenomena is correct,
this would not seem a strong indication. It
should be added that catatonia lacks a clear
definition and there would be a danger of
moving too readily to heroic interventions
of unproven value.” Instead, they recom-
mend the pharmacological and psycholog-
ical approaches for obsessive–compulsive
disorders unassociated with autism (or
catatonia). However, the vignette and sim-
ilar cases support the use of ECT in cases
of ASD with catatonia, also with concur-
rent onset or increase of obsessions and
compulsions. Of course, unfounded ethical
objections to pediatric ECT, legal restric-
tions on pediatric ECT, lack of access to
ECT in general, and stigma remain salient
obstacles to effective treatment of catatonia
in these challenging patients (29, 30).
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